Acupuncture for Alopecia Areata: Limited Evidence with Modest Signals in Asian Trials

Alopecia areata (AA) is an organ-specific autoimmune disease characterized by patchy hair loss on the scalp, beard, or other hair-bearing áreas. In extensive forms, it can progress to total or universal alopecia, with substantial psychosocial impact. Standard treatment includes topical, intralesional, or systemic corticosteroids, minoxidil, topical immunotherapy (DPCP), and — more recently — oral JAK inhibitors (baricitinib, ritlecitinib), which show strong efficacy in extensive forms. Acupuncture has been investigated as an adjunct, primarily in Asian trials.

What the Literature Shows

Meta-analyses of predominantly Asian trials suggest a modestly higher repigmentation rate (SALT-50, SALT-75) in groups that received acupuncture as an adjunct to topical or intralesional corticosteroid, compared with corticosteroid alone. Effect sizes are small, and the literature is dominated by small trials with methodological limitations — blinding is difficult and controls vary across studies. No head-to-head comparisons with modern JAK inhibitors exist. In severe AA (total/universal alopecia), the evidence base is virtually nonexistent.

Key Limitations

The literature has meaningful limitations: a predominance of Asian trials with risk of bias, heterogeneous definitions of treatment response, no comparisons with current first-line therapy (JAK inhibitors), and short follow-up periods. For severe AA — particularly total and universal alopecia — oral JAK inhibitors (baricitinib, approved by the FDA and the EMA; ritlecitinib, approved by the FDA) represent the most important therapeutic advance in this condition in recent decades, and acupuncture has no demonstrated role in this setting.